Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

baxalta innovations gmbh - von willebrandov faktor, humani; koagulacijski faktor viii, humani - prašek in vehikel za raztopino za injiciranje - von willebrandov faktor, humani 750 i.e. / 1 viala  koagulacijski faktor viii, humani1000 i.e. / 1 viala; koagulacijski faktor viii, humani 1000 i.e. / 1 viala - kombinacija von willebrandovega faktorja in koagulacijskega faktorja viii

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

baxalta innovations gmbh - von willebrandov faktor, humani; koagulacijski faktor viii, humani - prašek in vehikel za raztopino za injiciranje - von willebrandov faktor, humani 375 i.e. / 1 viala  koagulacijski faktor viii, humani500 i.e. / 1 viala; koagulacijski faktor viii, humani 500 i.e. / 1 viala - kombinacija von willebrandovega faktorja in koagulacijskega faktorja viii

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

baxalta innovations gmbh - koagulacijski faktor ix, humani; koagulacijski faktor ix, humani - prašek in vehikel za raztopino za injiciranje/infundiranje - koagulacijski faktor ix, humani 600 i.e. / 1 viala  koagulacijski faktor ix, humani600 i.e. / 1 viala; koagulacijski faktor ix, humani 600 i.e. / 1 viala - koagulacijski faktor ix

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prašek in vehikel za raztopino za injiciranje ali infundiranje - koagulacijski faktor ix

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

baxalta innovations gmbh - von willebrandov faktor, humani; koagulacijski faktor viii, humani - prašek in vehikel za raztopino za injiciranje - von willebrandov faktor, humani 190 i.e. / 1 viala  koagulacijski faktor viii, humani250 i.e. / 1 viala; koagulacijski faktor viii, humani 250 i.e. / 1 viala - kombinacija von willebrandovega faktorja in koagulacijskega faktorja viii

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

baxalta innovations gmbh - koagulacijski faktor ix, humani; koagulacijski faktor ix, humani - prašek in vehikel za raztopino za injiciranje/infundiranje - koagulacijski faktor ix, humani 1200 i.e. / 1 viala  koagulacijski faktor ix, humani1200 i.e. / 1 viala; koagulacijski faktor ix, humani 1200 i.e. / 1 viala - koagulacijski faktor ix

Evropska unija - slovenščina - EMA (European Medicines Agency)

ceva santé animale - inaktivirana cepiva coxiella burnetii, sev devet milj - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - prašiči - za aktivno imunizacijo prašičev od 7 tednov dalje za preprečevanje smrtnosti in zmanjšanje okužb in bolezni, ki jih povzroča virus klasične prašičje kuge (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Evropska unija - slovenščina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - prašiči - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.